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Abstract
Background: Adefovir Dipivoxil (ADV) is an important agent to suppress hepatitis B virus (HBV) replication with
suboptimal effect on virological and serological response. To optimize Adefovir therapy in chronic hepatitis B (CHB)
patients with hepatitis B e antigen (HBeAg) positive, we studied the baseline parameters and on-treatment HBV
DNA for favorable outcomes.
Methods: 48 patients were enrolled in the study and followed up for 5 years prospectively. Baseline characteristics,
virological, serological and biochemical parameters as well as on treatment HBV DNA were assessed in prediction
of favorable outcomes.
Results: 1. The patients with baseline alanine aminotransferase (ALT) ≥5 × the upper limit of normal (ULN, 40 IU/L)
had higher rates of viral response (VR), HBeAg loss and HBeAg seroconversion at year 5 compared to the patients
with ALT < 5 × ULN (VR: 75% vs 43.8%, p = 0.035; HBeAg loss: 43.9% vs 13.8%, p = 0.017; HBeAg seroconversion:
37.9% vs 13.8%, p = 0.035); Patients with baseline HBV DNA < 10
9 copies/ml and ALT ≥3 × ULN had more chance
of HBeAg seroconversion (40.9% vs 8.7%, p = 0.012), while in patients with HBeAg < 800 s/co or HBsAg < 5000 IU/
ml higher rates of HBeAg loss were achieved. 2. HBV DNA level < 10
4 copies/ml at week 24 was predictive for VR
(96.0% vs 40.9%, P < 0.001), HBeAg loss (84.0% vs 36.3%, P = 0.001) and HBeAg seroconversion (36.0% vs 9.1%, P =
0.030).
Conclusions: ADV treatment should be started for patients with baseline ALT≥5 × ULN or patients with ALT≥3×
ULN and HBV DNA < 10
9 copies/ml. Lower level of HBeAg(< 800 s/co) and HBsAg(< 5000 IU/ml) may be regarded
as referenced factors. In patients with serum HBV DNA < 10
4 copies/ml at week 24 the therapy should continue,
and a favorable outcome may be achieved in 5 years or longer.
Keywords: hepatitis B, chronic, Adefovir Dipivoxil, therapy, hepatitis B virus, hepatitis Be antigen positive, predictor
Background
Adefovir Dipivoxil (ADV) is a nucleotide analogue for
treatment of hepatitis B. Long term treatment with
ADV is well tolerated and may produce long-term viro-
logical, biochemical, serological and histological
improvement [1]. Compared with lamivudine (LAM)
and telbivudine, ADV correlated resistance develops less
frequently but ADV has less potent activity against
hepatitis B virus (HBV). It has been reported that the
rates of HBV DNA negative, hepatitis B e antigen
(HBeAg) loss and HBeAg seroconversion were 39%, 58%
and 48% respectively in the subjects with HBeAg posi-
tive chronic hepatitis B (CHB) treated with ADV 10 mg
once daily for 5 years, and 66% of them achieved alanine
aminotransferase (ALT) normalization and 20% devel-
opped HBV mutant [2]. These data highlighted an
urgent need to identify the predictors that will help to
find candidates who may likely benefit from ADV or,
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ment is needed. Recently, It has been reported that
baseline and on-treatment serum HBV DNA were sig-
nificant predictors for sustained viral response in CHB
patients with pegylated interferon(Peg-IFN) and nucleos
(t)ide analogues(NAs) treatment [3-8]. In the GLOBE
study of HBeAg-positive patients treated with telbivu-
dine, HBV DNA negative at week 24 was more predic-
tive for responses than other parameters [9]. Similar
results were reported in LAM and ADV therapies
[10,11]. However, the association of these predictors
with effect of long term ADV treatment has rarely been
reported.
The aim of this study is to assess baseline and on-
treatment serum markers in prediction of long term
response in the early phase of treatment with ADV
among HBeAg-positive CHB patients so as to identify
the most beneficial patients from ADV treatment and
optimize the therapy.
Methods
Subject population
48 HBeAg-positive CHB patients who enrolled in the
study were treated with ADV (provided by GlaxoS-
mithKline) and followed up for 5 years. All patients
were seropositive for hepatitis B surface antigen
(HBsAg) and HBeAg for more than 6 months and with
baseline ALT ≥1.2 × the upper limit of normal (ULN,
40 IU/L) and HBV DNA ≥10
6 copies/ml before treat-
ment. Criteria for exclusion included serum creatinine
greater than 1.5 mg/dl (130μmol/L); seropositivity for
hepatitis C or D virus or human immunodeficiency
virus. No patients received LAM or any other anti-HBV
therapy within 6 months prior to treatment. Other treat-
ments were not used during the therapy. Written
informed consent was obtained from all patients and the
study was approved by the Ethical Committee of Jinan
Infectious Disease Hospital.
Study Design
All patients were followed up at weeks 4, 12, 24, 52
and every 12-16 weeks after week 52 for detection of
serum biochemical parameters, serum viral load
(Roche COBAS Amplicore HBV Monitor PCR assay,
lower limit of detection 300 copies/ml) and HBV mar-
kers (micro particle enzyme immunoassay with
ABBOTT reagents). DNA sequencing and phylogenetic
analysis of HBV genome were evaluated at baseline.
Serum samples at first time point from subjects who
experienced a breakthrough of HBV DNA (HBV DNA
level increased by 1 log10 copies/ml or more than the
treatment nadir) were assessed for the development of
ADV-associated mutations (rtA181V and rtN236T) in
the HBV polymerase.
Efficacy End Points
The primary efficacy endpoints in this study were
HBeAg seroconversion defined as combination of
HBeAg loss and development of hepatitis B e antibody
accompanied by HBV DNA negative(< 300 copies/ml).
The secondary efficacy endpoints are HBeAg loss and
viral response (VR) defined as HBV DNA negative.
Statistical Analyses
Descriptive statistics such as the mean, median, and
standard deviation for each continuous variable and fre-
quencies for each categorical variable were used to sum-
marize the data as well as detect outliers and missing
values. The associations of baseline and on-treatment
parameters with virological, serological and biochemical
responses were assessed using Chi-square tests or Fish-
er’s exact tests. All p values were calculated with two-
sided significance level of 0.05. Data analyses were per-
formed using SAS 9.2 (SAS Institute, Inc, Cary, North
Carolina).
Results
1. Baseline characteristics of demographic, clinical and
laboratory data
Except for 1 woman who withdrew because of preg-
nance at week 104, 47 patients completed 5 years’ follow
up. All patients were ethnically Chinese and HBV geno-
type C positive. The baseline demographic, clinical and
virological data are shown in Table 1.
2. Virological, serological and biochemical response
Of 47 patients, the rates of VR, accumulative HBeAg
loss, HBeAg seroconversion and ALT normalization in
the end of the fifth year were 66.0%, 36.2%, 23.4% and
70.2%, respectively. The rates of HBeAg loss increased
over time, and the proportion of patients with ALT nor-
malization and HBV DNA < 300 copies/ml achieved
maximal values after 2 and 4 years respectively (Figure
1). Virus breakthrough was found in 4 patients but
ADV correlated variants were detectable only in 3 of
them.
Table 1 Baseline characteristics of demographic, clinical
and laboratory data
variables
Age in years, mean ± SD 31.7 ± 6.6
Male, % 85.1%
HBV genotype C, % 100%
Baseline ALT, IU/L 216.3 ± 169.7
Baseline HBV DNA(log10copies/ml) 8.5 ± 0.8
Baseline HBeAg(log10) 2.8 ± 0.4
BaselineHBsAg(log10) 3.7 ± 0.5
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response
We evaluated baseline characteristics such as ALT, HBV
DNA, HBsAg and HBeAg level in prediction of 5-year
response and found baseline ALT was a potential pre-
dictor of outcome. Patients with baseline ALT ≥5×
ULN were more likely to have HBeAg seroconversion,
HBeAg loss and VR than patients with ALT < 5 × ULN
(Table 2), while in patients with HBeAg < 800 s/co or
HBsAg < 5000 IU/ml higher rates of HBeAg loss were
achieved. The baseline HBeAg level predicted VR too, as
88.9% patients with baseline HBeAg < 800 s/co became
HBV DNA negative, whereas baseline HBV DNA level
alone was not a significant predictor for HBeAg sero-
conversion, HBeAg loss or VR.
Even so, there was a trend that the rate of VR in the 5
years decreased with the higher levels of baseline viral
load (Figure 2). In subgroup analyses, we found in
patients with baseline HBV DNA < 10
9 copies/ml, ALT
was positively associated with VR and HBeAg serocon-
version. The rate of HBeAg seroconversion was
significantly higher in patients with ALT ≥3×U L N
when compared to the patients with ALT < 3 × ULN
(40.9% vs 8.7%, p = 0.012).
4. Impact of on-treatment HBV DNA on outcomes
The relationships between on-treatment HBV DNA levels
and 5-year outcomes were presented in Table 3. Patients
with serum HBV DNA level < 4 log10 copies/ml at week
24 had higher rates of HBeAg seroconversion, HBeAg loss
and VR compared to the patients with serum HBV DNA
≥4 log10 copies/ml. The drop of the serum HBV DNA ≥3
log10 copies/ml at week 4 and HBV DNA undetectable at
week 52 can predict VR and HBeAg loss while the drop of
the serum HBV DNA ≥4l o g 10 copies/ml at week 12 was
significantly associated with the increased rates of HBeAg
loss and HBeAg seroconversion.
5. Resistance to ADV
Four patients experienced viral breakthrough at week
104, 184, 208, 260 respectively. HBV DNA rebounded to
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Figure 1 Virological, serological and biochemical response over
time. The rates of VR, accumulative HBeAg loss, HBeAg
seroconversion increased with time.
Table 2 Baseline predictors and 5-year outcomes
VR % P-value HBeAg loss % P-value HBeAg seroconversion % P-value
ALT≥5 × ULN 75.0% 0.035 43.9% 0.017 37.9% 0.035
ALT < 5 × ULN 43.8% 13.8% 13.8%
HBeAg < 800 s/co 88.9% 0.027 77.8% 0.045 27.8% 0.831
HBeAg≥800 s/co 47.6% 38.0% 19.0%
HBsAg < 5000 IU/ml 80.0% 0.132 80.0% 0.026 27.8% 0.200
HBsAg≥ 5000 IU/ml 59.3% 48.1% 24.1%
HBV DNA < 9 log10 copies/ml 71.9% 0.494 61.8% 0.621 26.5% 0.702
HBV DNA≥ 9 log10copies/ml 69.2% 53.9% 15.4%
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Figure 2 Viral response in patients with different levels of
baseline viral load. The rate of VR in the 5 years decreased with
the higher levels of baseline viral load although no statistical
significance was observed.
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7 copies/ml, and ALT flares were
f o u n di n3p a t i e n t sb u tn o n eo ft h e md e v e l o p p e dl i v e r
decompensation. ADV correlated mutations were
d e t e c t e di n3o ft h e4p a t i e n t s( 1o ft h e mw i t hN 2 3 6 T
and another 2 with combination of A181T/V and
N236T mutations in HBV DNA polymerase). None of
the patients who achieved HBV DNA < 4 log copies/ml
at week 24 experienced viral breakthrough. All four
patients were then given additional LAM for combina-
tion therapy.
6. Safety analysis
Four patients had an increase in serum creatinine of
more than the peak value of normal (1.5 mg/dl), but the
abnormality was not confirmed by a consecutive sample
test. Three patients had slightly elevated serum uric acid
in incontinuous samples. No action was taken regarding
study medication dosing.
Discussion
The response of ADV monotherapy for HBeAg positive
CHB patients is less satisfying comparing with that of
other oral NAs, but in many Asian countries like China,
tenofovir is unavailable, ADV is still the only nucleotide
analogue without cross resistance to other NAs to date
[12-14]. The optimization of ADV therapy according to
patients’ baseline and on-treatment parameters may be a
feasible strategy to increase the response. It was ever
reported that ADV might provide additional benefits for
HBeAg seroconversion in patients with pre-treatment
HBV DNA levels between 10
7 and 10
8 copies/ml [15].
Subgroup analysis of GLOBE Study with telbivudine
revealed that patients with ALT≥2×U L Na n dH B V
DNA < 10
9 copies/ml had more chance of VR, HBeAg
seroconversion and ALT nomalization at year 2 [16].
There were also similar reports about long term LAM
therapy [10]. In our study baseline factors such as ALT
predicted long term response to ADV therapy. Patients
with higher baseline ALT (≥5 × ULN) had more chance
of optimal outcomes, and lower levels of HBeAg (< 800
s/co) and HBsAg(< 5000 IU/ml) also predicted HBeAg
loss. In addition, there was a trend that patients with
lower HBV DNA level might have higher rates of VR,
HBeAg loss and HBeAg seroconversion although no sta-
tistical significance was observed in our study. Our find-
ings may be limited by the relatively small sample size.
When we combined baseline ALT and HBV DNA, we
found that patients with baseline HBV DNA < 10
9
copies/ml and ALT ≥3 × ULN had more favorable out-
comes. An elevated ALT level indicates increased clear-
ance to HBV infected hepatocytes. It was reported that
Chinese patients with ALT > 5 × ULN had high rate of
spontaneous HBeAg seroconversion even without treat-
ment [17], but treatment with anti-virus medicaments
can improve the chance of HBeAg seroconversion and
decrease the disease progression which has been proved
in many clinical studies [2,18-20]. Similarly, HBeAg level
may reflect the clearance capability of a HBV infected
body to HBV infected hepatocytes [21,22]. The signifi-
cance of HBsAg in treatment of patients with CHB is
being paid close attention to recently. HBsAg may
reflect the level of cccDNA in liver and the decrease
during treatment with pegylated interferon alfa-2a may
predict the sustained viral response [23,24]. More stu-
dies are needed to elucidate HBsAg variations during
treament with NAs. In our study patients with lower
level of baseline HBeAg and HBsAg had more chance of
HBeAg loss which indicaties that baseline HBeAg and
HBsAg may be regarded as subsidiary parameters in
pretreatment evaluation.
Early HBV DNA reduction may also contribute to VR
and HBeAg seroconversion in some studies [11,15,25].
It’s generally accepted that therapy can be optimized by
monitoring of serum HBV DNA levels during treatment
with oral NAs and week 24 is the most important time
point recommended to assess efficacy in LAM and telbi-
vudine therapy [26], but whether it’s reasonable in treat-
ment of suboptimal antiviral drug like ADV remains
controversial. We selected week 4, 12, 24 and 52 as time
points in our study and found that serum HBV DNA <
4l o g 10 copies/ml at week 24 was predictive for VR,
HBeAg loss and HBeAg seroconversion after 5-year
treatment, The drop of HBV DNA from baseline ≥3
log10 copies/ml at week 4, ≥ 4l o g 10 copies/ml at week
Table 3 Impact of on-treatment HBV DNA on 5-year outcomes
N VR P-value HBeAg loss P-value HBeAg seroconversion P-value
drop of HBV DNA ≥3 log10copies/ml at week 4 12 91.7% 0.06 91.7% 0.013 41.7% 0.083
drop of HBV DNA < 3 log10copies/ml at week 4 35 62.6% 51.4% 17.1%
drop of HBV DNA ≥4 log10copies/ml at week 12 20 85.0% 0.366 80.0% 0.028 45.0% 0.006
drop of HBV DNA < 4 log10copies/ml at week 12 27 60.0% 48.0% 7.4%
DNA level < 4 log10copies/ml at week 24 25 96.0% < 0.001 84.0% 0.001 36.0% 0.030
DNA level ≥ 4 log10copies/ml at week 24 22 40.9% 36.3% 9.1%
DNA negative at week 52 27 100% < 0.001 88.9% < 0.001 33.3% 0.062
DNA positive at week 52 20 45.0% 20.0% 10.0%
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Page 4 of 612 and HBV DNA turning negative at week 52 can also
predict favorable outcomes although not as optimal as
HBV DNA < 4 log10 copies/ml at week 24. None of the
patients who achieved HBV DNA < 4 log10 copies/ml at
week 24 experienced viral breakthrough. Accordingly we
recommend serum HBV DNA level < 4 log10copies/ml
at week 24 as one of the major predictors for long term
outcomes in patients with ADV therapy.
Our study has some limitations because of its small
sample size and lack of a control group. However, in
our study most patients completed 5 years’ follow-up,
and the detection method was advanced. The findings
m a yg i v es o m ee v i d e n c et om a n a g eH B e A gp o s i t i v e
patients who intend to accept or have already accepted
ADV therapy.
Conclusions
ADV treatment may be initiated to patients with base-
line ALT≥5×U L No rp a t i e n t sw i t hA L T ≥3×U L Na n d
HBV DNA < 10
9 copies/ml, lower level of HBeAg(< 800
s/co) or HBsAg (< 5000 IU/ml) may be regarded as
referenced factors. Patients will be followed up regularly
and long term outcome may be predicted according to
on-treatment HBV DNA. For patients with HBV DNA
level < 10
4 copies/ml at week 24 therapy should con-
tinue and favorable outcomes may be achieved in 5
years or longer. For others with HBV DNA ≥10
4 copies/
ml at week 24, some modifications for the therapeutic
regimen such as addition or switch to another agent
should be considered to enhance the long term
response.
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